Abivax S.A.
ABVX • Biotechnology
$88.13
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$7.02B
Growth
-100.0%
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.07Healthy liquidity · 8.75Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Sep 23, 2026, 12:05 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$88.13
Change0.00%
Shares Out79.65M
Market Cap$7.02B
52W Range69.81 - 148.83
Beta-0.25
P/E-21.29
P/S0.00
P/B15.72
P/FCF-45.92
EV/Sales0.00
EV/EBITDA-24.93
Price$88.13
Change0.00%
Shares Out79.65M
Market Cap$7.02B
52W Range69.81 - 148.83
Beta-0.25
P/E-21.29
P/S0.00
P/B15.72
P/FCF-45.92
EV/Sales0.00
EV/EBITDA-24.93
EV/FCF-48.10
Earnings Yield-4.70%
FCF Yield-2.18%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.07
Current Ratio8.75
Quick Ratio8.75
Revenue 5Y-100.00%
Target$156.00
Target Upside77.01%
Target Median$156.50
Target Range118.00 - 180.00
Volume2.53M
Avg Volume1.75M
EPS Surprise0.22
Investment DNA
How strong this company looks for long-term investors
34
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Manageable debt level · 0.07Healthy liquidity · 8.75Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 13 analyst votes · 2026-10-19
96/100
Bullish
Bullish
12
Hold
1
Bearish
0
Price Target
2026-09-23
Low
$118.00
Mean
$156.00
Median
$156.50
High
$180.00
🧾
No insider activity
No recent insider transactions available.